- Home
- VCIC vs OSUR Comparison
VCIC vs OSUR Comparison
Compare VCIC & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIC
- OSUR
- Stock Information
- Founded
- VCIC 2024
- OSUR 2000
- Country
- VCIC United States
- OSUR United States
- Employees
- VCIC N/A
- OSUR N/A
- Industry
- VCIC
- OSUR Medical/Dental Instruments
- Sector
- VCIC
- OSUR Health Care
- Exchange
- VCIC NYSE
- OSUR Nasdaq
- Market Cap
- VCIC 293.0M
- OSUR 289.4M
- IPO Year
- VCIC 2024
- OSUR 1986
- Fundamental
- Price
- VCIC $10.03
- OSUR $3.91
- Analyst Decision
- VCIC
- OSUR Buy
- Analyst Count
- VCIC 0
- OSUR 3
- Target Price
- VCIC N/A
- OSUR $6.67
- AVG Volume (30 Days)
- VCIC 6.6K
- OSUR 907.9K
- Earning Date
- VCIC 01-01-0001
- OSUR 11-06-2024
- Dividend Yield
- VCIC N/A
- OSUR N/A
- EPS Growth
- VCIC N/A
- OSUR N/A
- EPS
- VCIC N/A
- OSUR 0.15
- Revenue
- VCIC N/A
- OSUR $224,263,000.00
- Revenue This Year
- VCIC N/A
- OSUR N/A
- Revenue Next Year
- VCIC N/A
- OSUR N/A
- P/E Ratio
- VCIC N/A
- OSUR $25.98
- Revenue Growth
- VCIC N/A
- OSUR N/A
- 52 Week Low
- VCIC $9.96
- OSUR $3.72
- 52 Week High
- VCIC $10.03
- OSUR $8.45
- Technical
- Relative Strength Index (RSI)
- VCIC N/A
- OSUR 47.69
- Support Level
- VCIC N/A
- OSUR $3.78
- Resistance Level
- VCIC N/A
- OSUR $4.18
- Average True Range (ATR)
- VCIC 0.00
- OSUR 0.16
- MACD
- VCIC 0.00
- OSUR 0.03
- Stochastic Oscillator
- VCIC 0.00
- OSUR 37.21
About VCIC VINE HILL CAP INVT CORP
Vine Hill Capital Investment Corp is a blank check company.
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.